HF
TNGX icon

HRT Financial’s Tango Therapeutics TNGX Stock Holding History

HRT Financial’s Portfolio TNGX Stock Details TNGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-31,146
Closed -$96K – 3392
2024
Q4 		$96K Buy
+31,146
New +$145K ﹤0.01% 2044
2023
Q2 		– Sell
-11,594
Closed -$45K – 3280
2023
Q1 		$45K Buy
+11,594
New +$67.3K ﹤0.01% 2133
2022
Q4 		– Sell
-90,407
Closed -$327K – 3153
2022
Q3 		$327K Buy
+90,407
New +$386K ﹤0.01% 1943
2022
Q1 		– Sell
-23,517
Closed -$257K – 3861
2021
Q4 		$257K Buy
+23,517
New +$283K ﹤0.01% 2365
2021
Q3 		– Sell
-14,733
Closed -$167K – 3760
2021
Q2 		$167K Buy
14,733
+733
+5% +$8.23K ﹤0.01% 2455
2021
Q1 		$155K Hold
14,000
– – ﹤0.01% 2376
2020
Q4 		$160K Sell
14,000
-2,141
-13% -$22.5K ﹤0.01% 1555
2020
Q3 		$174K Buy
+16,141
New +$165K 0.01% 1403

Other funds holding TNGX

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
GS
Gilead Sciences Foster City, California $2.12B AUM 143.53% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

HRT Financial's TNGX Position: Q1 2025 in Review

HRT Financial sold out of Tango Therapeutics (TNGX) in Q1 2025, closing a stake of 31,146 shares — an estimated $96K sold.

HRT Financial first reported a position in TNGX in Q3 2020 and held it in 8 quarters. The position peaked at $327K in Q3 2022. 122 funds tracked by Wall St. Rank hold TNGX as of Q1 2025.

  • HRT Financial reported no remaining Tango Therapeutics position as of Q1 2025 after selling out during the quarter.
  • HRT Financial sold 31,146 Tango Therapeutics shares in Q1 2025, an estimated $96K.
  • HRT Financial first reported a position in Tango Therapeutics in Q3 2020 and held it in 8 quarters.
  • HRT Financial's Tango Therapeutics position peaked at $327K in Q3 2022.
  • 122 funds tracked by Wall St. Rank held Tango Therapeutics as of Q1 2025.

Based on HRT Financial's 13F filing for Q1 2025, filed 15 May 2025.